Soleno Therapeutics price target raised to $110 from $100 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says Citizen Petitions usually do not result in withdrawals of products from the U.S. market, as over 80% of those filed since 2001 have been denied or failed to elicit a response from the FDA. It updated the company’s model post the Q2 report.